Eyepoint Pharmaceuticals Stock Fundamentals
| EYPT Stock | USD 9.23 0.28 3.13% |
Eyepoint Pharmaceuticals fundamentals help investors to digest information that contributes to Eyepoint Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Eyepoint Stock. The fundamental analysis module provides a way to measure Eyepoint Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eyepoint Pharmaceuticals stock.
At this time, Eyepoint Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Selling And Marketing Expenses is likely to gain to about 17 M in 2024, despite the fact that EBIT is likely to grow to (66 M). Eyepoint | Select Account or Indicator |
Eyepoint Pharmaceuticals Company Operating Margin Analysis
Eyepoint Pharmaceuticals' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Eyepoint Pharmaceuticals Operating Margin | (3.11) % |
Most of Eyepoint Pharmaceuticals' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eyepoint Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Eyepoint Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Eyepoint Pharmaceuticals has an Operating Margin of -3.1117%. This is 91.13% lower than that of the Pharmaceuticals sector and 97.22% lower than that of the Health Care industry. The operating margin for all United States stocks is 43.53% lower than that of the firm.
Eyepoint Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Eyepoint Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Eyepoint Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Eyepoint Pharmaceuticals competition to find correlations between indicators driving Eyepoint Pharmaceuticals's intrinsic value. More Info.Eyepoint Pharmaceuticals is rated # 4 in return on equity category among its peers. It is rated # 5 in return on asset category among its peers . At this time, Eyepoint Pharmaceuticals' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Eyepoint Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Eyepoint Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eyepoint Pharmaceuticals' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eyepoint Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eyepoint Pharmaceuticals by comparing valuation metrics of similar companies.Eyepoint Pharmaceuticals is currently under evaluation in operating margin category among its peers.
Eyepoint Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Eyepoint Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Eyepoint Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Eyepoint Fundamentals
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (2.27) % | ||||
| Operating Margin | (3.11) % | ||||
| Current Valuation | 378.98 M | ||||
| Shares Outstanding | 68.25 M | ||||
| Shares Owned By Insiders | 1.14 % | ||||
| Shares Owned By Institutions | 93.43 % | ||||
| Number Of Shares Shorted | 9.68 M | ||||
| Price To Earning | (2.82) X | ||||
| Price To Book | 2.79 X | ||||
| Price To Sales | 13.36 X | ||||
| Revenue | 46.02 M | ||||
| Gross Profit | 26.95 M | ||||
| EBITDA | (69 M) | ||||
| Net Income | (70.8 M) | ||||
| Cash And Equivalents | 171.17 M | ||||
| Cash Per Share | 5.02 X | ||||
| Total Debt | 5.47 M | ||||
| Debt To Equity | 0.30 % | ||||
| Current Ratio | 6.16 X | ||||
| Book Value Per Share | 4.09 X | ||||
| Cash Flow From Operations | 1.88 M | ||||
| Short Ratio | 10.40 X | ||||
| Earnings Per Share | (1.99) X | ||||
| Target Price | 33.45 | ||||
| Number Of Employees | 121 | ||||
| Beta | 1.52 | ||||
| Market Capitalization | 610.85 M | ||||
| Total Asset | 355.18 M | ||||
| Retained Earnings | (742.15 M) | ||||
| Working Capital | 281.54 M | ||||
| Current Asset | 15.08 M | ||||
| Current Liabilities | 11.26 M | ||||
| Net Asset | 355.18 M |
About Eyepoint Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eyepoint Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eyepoint Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eyepoint Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 38.6 M | 36.7 M | |
| Total Revenue | 46 M | 48.3 M | |
| Cost Of Revenue | 4.6 M | 4.4 M | |
| Stock Based Compensation To Revenue | 0.26 | 0.35 | |
| Sales General And Administrative To Revenue | 0.87 | 0.83 | |
| Research And Ddevelopement To Revenue | 1.41 | 1.33 | |
| Capex To Revenue | 0.08 | 0.07 | |
| Revenue Per Share | 1.18 | 1.12 | |
| Ebit Per Revenue | (1.60) | (1.68) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Eyepoint Stock Analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.